Rheumatoid Arthritis
📧 Sign up to get email alerts when something new happens for Rheumatoid Arthritis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-12-26FDA Approved: RENFLEXIS — Supplemental Application (Organon LLC)
FDA approved a supplemental application for Renflexis (infliximab) submitted by Organon LLC.
-
FDA approval · 2023-12-15FDA Approved: HULIO — Supplemental Application (Biocon Biologics Inc)
The FDA approved a supplemental application for HULIO, Biocon Biologics' biosimilar adalimumab (adalimumab-fkJP).
-
FDA approval · 2023-12-14FDA Approved: CYCLOSPORINE — Original Application (Teva Pharmaceuticals, Inc.)
FDA approves Teva Pharmaceuticals' generic cyclosporine under an original application (ANDA 203880), expanding access to this immunosuppress…
-
CLINICAL_TRIALS trial_result · 2023-12-13Clinical Trial Update: Study Comparing Etanercept Plus Methotrexate to Either Etanercept or Methotrexate Alone in Rheumatoid Arthritis. [Phase 3]
Phase 3 trial comparing combination therapy (etanercept plus methotrexate) to monotherapy (etanercept or methotrexate) in active rheumatoid …
-
CLINICAL_TRIALS trial_result · 2023-12-11Clinical Trial Update: An Extension Study of WA19926 of the Long-Term Safety of Tocilizumab (RoActemra/Actemra) in Patients With Early Moderate to Severe Rheumatoid Arthritis [Phase 3]
An extension study reports the long-term safety data for tocilizumab in patients with early moderate to severe rheumatoid arthritis. Complet…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-12-05FDA Approved: PREDNISONE TABLETS, USP, 5 MG — Supplemental Application (Granulation Technology, Inc.)
FDA granted a supplemental approval for Prednisone Tablets, USP, 5 mg to authorize a granulation technology manufacturing change by Granulat…
-
FDA approval · 2023-11-30FDA Approved: ADALIMUMAB — Supplemental Application (CELLTRION USA, Inc.)
The FDA approved a supplemental Biologics License Application for the adalimumab biosimilar ADALIMUMAB-AATY from Celltrion USA, Inc., allowi…
-
CLINICAL_TRIALS trial_result · 2023-11-30Clinical Trial Update: Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs) [Phase 3]
Phase 3 trial evaluating GSK3196165 vs placebo and tofacitinib in adults with moderately to severely active rheumatoid arthritis who failed …
-
FDA approval · 2023-11-29FDA Approved: HYDROXYCHLOROQUINE SULFATE — Supplemental Application (Dr. Reddy's Laboratories Inc.)
FDA approved a supplemental application for HYDROXYCHLOROQUINE SULFATE from Dr. Reddy's Laboratories Inc.
-
CLINICAL_TRIALS trial_result · 2023-11-28Clinical Trial Update: An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy [Phase 3]
Phase 3 study evaluating subcutaneous tocilizumab with methotrexate or as monotherapy versus MTX in moderate-to-severe rheumatoid arthritis …
-
CLINICAL_TRIALS trial_result · 2023-11-27Clinical Trial Update: Alendronate Treatment of Osteoporosis in Rheumatoid Arthritis [Phase 2]
Phase 2 clinical trial investigating alendronate for osteoporosis in patients with rheumatoid arthritis has completed.
-
CLINICAL_TRIALS trial_result · 2023-11-22Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Rheumatoid Arthritis [Phase 3]
Phase 3 trial update for SHR0302 assessing efficacy and safety in rheumatoid arthritis has completed.
-
CLINICAL_TRIALS trial_result · 2023-11-22Clinical Trial Update: A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis [Phase 2]
Phase 2 trial of PF-04171327 for rheumatoid arthritis completed; results posted.
-
CLINICAL_TRIALS trial_result · 2023-11-21Clinical Trial Update: Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis [Phase 2]
Phase 2 trial update evaluating strategies to prevent clinically apparent rheumatoid arthritis. The study was terminated and results have be…
-
CLINICAL_TRIALS trial_result · 2023-11-18Clinical Trial Update: Adalimumab Dose Reduction Aiming Low Serum Concentration With Control of Disease Activity [Phase 4]
Phase 4 trial evaluating adalimumab dose reduction to achieve low serum concentrations while maintaining disease control in rheumatoid arthr…
-
CLINICAL_TRIALS trial_result · 2023-11-18Clinical Trial Update: A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products [Phase 3]
A Phase III trial update evaluating transition from DRL Rituximab to a reference product in rheumatoid arthritis has completed with results …
-
CLINICAL_TRIALS trial_result · 2023-11-18Clinical Trial Update: BARIcitinib Cognitive Emotional and Neural signaTuRE [Phase 4]
Phase 4 clinical trial update for bari citinib in rheumatoid arthritis has been terminated.
-
CLINICAL_TRIALS trial_result · 2023-11-18Clinical Trial Update: The Efficacy and Safety of Tofacitinib (TF) With Iguratimod (IGU) on RA [Phase 4]
Phase 4 trial assessing the efficacy and safety of tofacitinib with iguratimod in rheumatoid arthritis has been completed.
-
CLINICAL_TRIALS trial_result · 2023-11-18Clinical Trial Update: The Clinical Efficacy and Safety of Iguratimod in RA and Early RA Patients for 6 Months Treatment [Phase 4]
Phase 4 clinical trial update evaluating the efficacy and safety of iguratimod in rheumatoid arthritis and early rheumatoid arthritis over 6…
-
CLINICAL_TRIALS trial_result · 2023-11-18Clinical Trial Update: A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs [Phase 3]
A Phase 3 trial comparing TLL-018 to tofacitinib in rheumatoid arthritis patients with inadequate response or intolerance to bDMARDs is ongo…
-
CLINICAL_TRIALS trial_result · 2023-11-18Clinical Trial Update: The Efficacy and Safety of Tacrolimus in Refractory Rheumatoid Arthritis Patients for 6 Months and Long-term Treatment [Phase 4]
Phase 4 trial update on tacrolimus for refractory rheumatoid arthritis examines efficacy and safety over 6 months with long-term treatment.
-
CLINICAL_TRIALS trial_result · 2023-11-18Clinical Trial Update: Efficacy and Safety of Baricitinib for the Treatment of Moderate to Severe Rheumatoid Arthritis [Phase 4]
Phase 4 trial update evaluating the efficacy and safety of Baricitinib for moderate to severe rheumatoid arthritis.
-
CLINICAL_TRIALS trial_result · 2023-11-18Clinical Trial Update: Using Adalimumab Serum Concentration to Choose a Subsequent Biological DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment [Phase 4]
Phase 4 trial evaluating using adalimumab serum concentration to guide selection of a subsequent biological DMARD in patients with rheumatoi…
-
CLINICAL_TRIALS trial_result · 2023-11-13Clinical Trial Update: A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis [Phase 1]
Phase 1 study assessing pharmacokinetics of certolizumab pegol in adults with active rheumatoid arthritis completed with results posted.
-
FDA approval · 2023-11-08FDA Approved: CIMZIA — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for CIMZIA (certolizumab pegol) from UCB, Inc., updating its labeling and/or indications.